Durvalumab, an anti-PDL-1 injectable treatment, has just been approved in the EU as monotherapy for treatment of locally advanced, unresectable non-small cell lung cancer in adults whose tumours express PD-L1 ≥1% and who have not progressed following platinum-based chemoradiation therapy.